Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5210679 | 0.97 | CFD (0.46) | CFDF2KMT2ATSHRTPSAB1 | |
| Trifluoroacetic Acid SCHEMBL5243817 | 0.94 | TPSAB1 (0.40) | CFDF2TMPRSS6KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL8043425 | 0.94 | CFD (0.46) | CFDF2KMT2ATSHRTPSAB1 | |
| Trifluoroacetic Acid SCHEMBL5208605 | 0.93 | KMT2A (0.47) | KMT2AMEN1MAPTTPSAB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5244116 | 0.93 | CFD (0.43) | CFDF2KMT2ATSHRTPSAB1 | |
| Trifluoroacetic Acid SCHEMBL5216743 | 0.91 | TPSAB1 (0.39) | CFDKMT2AMAPTTPSAB1 | |
| Trifluoroacetic Acid SCHEMBL5214385 | 0.91 | LMNA (0.46) | KMT2AMEN1MAPTTPSAB1 | |
| Trifluoroacetic Acid SCHEMBL5210202 | 0.90 | LMNA (0.39) | KMT2AMAPTTPSAB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5247872 | 0.88 | RAB9A (0.41) | CFDKMT2AMAPTTPSAB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5216021 | 0.87 | SMN1; SMN2 (0.49) | KMT2AMEN1MAPTTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | CFD 143/4885F2 69/4885TMPRSS6 26/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | CFD 151/4885F2 122/4885TMPRSS6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.